Repository of Research and Investigative Information

Repository of Research and Investigative Information

Ilam University of Medical Sciences

COVID-19-associated pulmonary aspergillosis (CAPA) in Iranian patients admitted with severe COVID-19 pneumonia

Mon Feb 26 03:53:38 2024

(2023) COVID-19-associated pulmonary aspergillosis (CAPA) in Iranian patients admitted with severe COVID-19 pneumonia. Infection. pp. 223-230. ISSN 0300-8126

Full text not available from this repository.

Official URL: http://apps.webofknowledge.com/InboundService.do?F...

Abstract

Purpose Bacterial or virus co-infections with SARS-CoV-2 have been reported in many studies; however, the knowledge on Aspergillus co-infection among patients with COVID-19 was limited. This study was conducted to identify and isolate fungal agents and to evaluate the prevalence of pulmonary aspergillosis (CAPA) as well as antifungal susceptibility patterns of Aspergillus species in patients with COVID-19 admitted to Shahid Beheshti Hospital, Kashan, Iran. Methods The study involved 119 patients with severe COVID-19 pneumonia referred to the Shahid Beheshti Hospital, Kashan, Iran. A total of 17 Aspergillus spp. that were isolated from COVID-19 patients suspected of CAPA were enrolled in the study. CAPA was defined using ECMM/ISHAM consensus criteria. The PCR amplification of the beta-tubulin gene was used to identify the species. The antifungal activities of fluconazole, itraconazole, voriconazole, amphotericin B against Aspergillus spp. were evaluated according to the Clinical and Laboratory Standards Institute manual (M38-A3). Results From the 119 patients with severe COVID-19 pneumonia, CAPA was confirmed in 17 cases (14.3). Of these, 12 (70.6) were males and 5 (29.4) were females; the mean age at presentation was 73.8 years (range: 45-88 years; median = 77; IQR = 18). Aspergillus fumigatus (9/17; 52.9), Aspergillus flavus (5/17; 29.4), Aspergillus oryzae (3/17, 17.6), were identified as etiologic agents of CAPA, using the molecular techniques. Voriconazole and amphotericin B showed more activity against all isolates. Moreover, the MIC of fluconazole, itraconazole varied with the tested isolates. For 3 clinical isolates of A. fumigatus, 2 isolate of A. flavus and 3 A. oryzae, the MIC of fluconazole and itraconazole were >= 16 mu g/mL. Conclusions We observed a high incidence (14.3) of probable aspergillosis in 119 patients with COVID-19, which might indicate the risk for developing IPA in COVID-19 patients. When comparing patients with and without CAPA regarding baseline characteristics, CAPA patients were older (p =0 .024), had received more frequent systemic corticosteroids (p = 0.024), and had a higher mortality rate (p = 0.018). The outcome of CAPA is usually poor, thus emphasis shall be given to screening and/or prophylaxis in COVID-19 patients with any risk of developing CAPA.

Item Type: Article
Creators:
CreatorsEmail
Erami, M.UNSPECIFIED
Hashemi, S. J.UNSPECIFIED
Raiesi, O.UNSPECIFIED
Fattahi, M.UNSPECIFIED
Getso, M. I.UNSPECIFIED
Momen-Heravi, M.UNSPECIFIED
Ghazvini, R. D.UNSPECIFIED
Khodavaisy, S.UNSPECIFIED
Parviz, S.UNSPECIFIED
Mehri, N.UNSPECIFIED
Babaei, M.UNSPECIFIED
Keywords: Pulmonary aspergillosis COVID-19 Azole Antifungal drug resistance spectrum Infectious Diseases
Divisions:
Page Range: pp. 223-230
Journal or Publication Title: Infection
Journal Index: ISI
Volume: 51
Number: 1
Identification Number: https://doi.org/10.1007/s15010-022-01907-7
ISSN: 0300-8126
Depositing User: مهندس مهدی شریفی
URI: http://eprints.medilam.ac.ir/id/eprint/4405

Actions (login required)

View Item View Item